Adalimumab
- Generic Name
- Adalimumab
- Brand Names
- Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 331731-18-1
- Unique Ingredient Identifier
- FYS6T7F842
- Background
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced by recombinant DNA technology usi...
- Indication
Adalimumab is indicated for the following conditions:
Adalimumab has also been used off-label to treat Pyoderma gangrenosum.
- Associated Conditions
- Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Moderate to Severe Chronic Plaque Psoriasis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis, Non-infectious Intermediate, Posterior and Panuveitis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Pyoderma Gangrenosum
- Associated Therapies
- -
An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy
- Conditions
- Interventions
- First Posted Date
- 2012-05-07
- Last Posted Date
- 2016-08-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 90
- Registration Number
- NCT01592292
Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease
- Conditions
- Interventions
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2015-03-17
- Target Recruit Count
- 86
- Registration Number
- NCT01564823
- Locations
- 🇪🇸
Hospital General Dr. Negrín, Las Palmas de Gran Canaria, Islas Canarias, Spain
🇪🇸Hospital Reina Sofía, Córdoba, Spain
🇪🇸Hospital Arquitecto Marcide, Ferrol, La Coruña, Spain
Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants
- Conditions
- Interventions
- First Posted Date
- 2012-03-26
- Last Posted Date
- 2016-05-04
- Target Recruit Count
- 15
- Registration Number
- NCT01562951
- Locations
- 🇫🇷
CHRU Reims - Hospital Robert Debre, Reims, France
🇪🇸Hospital Universitario La Princesa, Madrid, Spain
🇪🇸Hospital Universitario Reina Sofia, Córdoba, Andalucía, Spain
Adalimumab-psoriasis and Small Bowel Lesions
- Conditions
- Interventions
- First Posted Date
- 2012-03-16
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- Innovaderm Research Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT01556672
- Locations
- 🇨🇦
Innovaderm Research Inc., Montreal, Quebec, Canada
🇨🇦Dr Isabelle Delorme, St-Hyacinthe, Quebec, Canada
🇨🇦Lynderm Research, Markham, Ontario, Canada
Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 193
- Registration Number
- NCT01505491
- Locations
- 🇳🇿
1297.1.002 Boehringer Ingelheim Investigational Site, Auckland, New Zealand
🇳🇿1297.1.001 Boehringer Ingelheim Investigational Site, Christchurch, New Zealand
Efficacy and Safety of Adalimumab for the Induction of Clinical Response in Ulcerative Colitis
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2012-10-30
- Lead Sponsor
- Clalit Health Services
- Target Recruit Count
- 200
- Registration Number
- NCT01494857
- Locations
- 🇮🇱
Lev Talpiot Clinic, Clalit health Services, Jerusalem, Israel
🇮🇱Zevulun Clinic, Clalit Health Services, Qiryat Bialik, Israel
🇮🇱Sherutey Briuth Clalit / Clalit HMO, Herzlyia, Israel
A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Janssen Inc.
- Target Recruit Count
- 293
- Registration Number
- NCT01483599
HUmira in Psoriatic Arthritis
- First Posted Date
- 2011-11-04
- Last Posted Date
- 2011-11-04
- Lead Sponsor
- Glostrup University Hospital, Copenhagen
- Target Recruit Count
- 42
- Registration Number
- NCT01465438
- Locations
- 🇩🇰
Copenhagen University Hospital, Glostrup, Glostrup, Copenhagen, Denmark
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2011-06-14
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 418
- Registration Number
- NCT01373151
- Locations
- 🇺🇸
Clinical Pharmacology Study Group, Worcester, Massachusetts, United States
🇺🇸Arthritis Associates Of Mississippi, Jackson, Mississippi, United States
🇺🇸Box Arthritis And Rheumatology Of The Carolinas, Pllc, Charlotte, North Carolina, United States
Efficacy Study of Adalimumab to Treat Interstitial Cystitis
- First Posted Date
- 2011-02-15
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- ICStudy, LLC
- Target Recruit Count
- 43
- Registration Number
- NCT01295814
- Locations
- 🇺🇸
Philip C. Bosch, MD, Escondido, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.